Xeris Biopharma Holdings (XERS) Short-term Investments (2020 - 2024)

Xeris Biopharma Holdings (XERS) has 5 years of Short-term Investments data on file, last reported at $10.2 million in Q3 2024.

• Quarterly Short-term Investments fell 48.72% year-over-year to $10.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $10.2 million (down 48.72% YoY) and the FY2023 annual result came in at $5.0 million, changed N/A from the prior year.
• Short-term Investments declined to $10.2 million in Q3 2024, from $20.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $96.2 million in Q4 2020 to a low of $5.0 million in Q4 2023.
• A 5-year average of $29.0 million and a median of $24.7 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments tumbled 72.16% — and 2023, when it surged 112.78%.
• Tracing XERS's Short-term Investments over 5 years: stood at $96.2 million in 2020, then plunged by 63.45% to $35.2 million in 2021, then tumbled by 73.48% to $9.3 million in 2022, then slumped by 46.35% to $5.0 million in 2023, then jumped by 103.32% to $10.2 million in 2024.
• The last three Short-term Investments figures came in at $10.2 million (Q3 2024), $20.0 million (Q2 2024), and $24.7 million (Q1 2024), per Business Quant data.